NCT03721172 2024-05-29
ADVANCE
Amgen
Phase 3 Completed
Clinical Trials
18 trialsNCT04571567 2022-04-11
A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis
Icahn School of Medicine at Mount Sinai
Phase 4 Completed
NCT00885196 2020-12-22
A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis
Novartis
Phase 2 Completed
NCT01490632 2019-09-27
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
Eli Lilly and Company
Phase 2 Completed
NCT01815424 2019-04-16
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT01582932 2019-01-22
Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis
Mayne Pharma International Pty Ltd
Phase 1 Completed
NCT01186744 2018-12-26
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT01241591 2018-12-26
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT03424629 2018-04-20
Safety and Efficacy of UC-MSCs in Patients With Plaque Psoriasis
Tianjin Ever Union Biotechnology Co., Ltd.
Phase 1 Unknown
NCT03340155 2017-11-13
BioUV2017
Medical University of Graz
Phase NA Unknown
NCT01163253 2017-06-26
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Terminated
NCT01313221 2017-03-15
REFINE
Amgen
Phase 3 Completed
NCT01831466 2015-11-25
Tofacitinib Ointment For Chronic Plaque Psoriasis
Pfizer
Phase 2 Completed
NCT01519089 2015-08-13
A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis
Pfizer
Phase 3 Completed
NCT01276639 2014-09-19
A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT01309737 2014-09-19
A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT00111449 2013-05-15
Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With Psoriasis
Amgen
Phase 3 Completed
NCT01077882 2012-07-06
OnderHUIDs
University Hospital, Ghent
Phase 4 Completed